Researchers discover that a key protein in aspirin may help pulverize an enzyme linked to neurodegenerative conditions like Alzheimers, Parkinsons and Huntingtons diseases is recommended that taking the common medication may help reduce Americans illnes hazard. In their research, published the coming week in the publication PLOS One, examine authors at Johns Hopkins University and Boyce Thompson Institute discovered that salicylic acid, a byproduct of aspirin, bind to the enzyme GAPDH ( Glyceraldehyde 3-Phosphate Dehydrogenase ), preventing it from moving into a cells nucleus where it would cause cell demise.
During oxidative stress, GAPDH is affected then enters the nucleus of neurons, where it affects protein turnover and have contributed to cell demise, causing neurodegenerative loss. The anti-Parkinson’s medication deprenyl already demonstrates GAPDH’s ability to prevent entry into the nucleus and the corresponding cell demise, according to a news release.
“The new examine establishes that GAPDH is a target for salicylate narcotics related to aspirin, and hence may be relevant to the therapeutic actions of such drugs, co-author Solomon Snyder, prof of neuroscience at Johns Hopkins University in Baltimore, said in the release.
Snyder, along with senior writer Daniel Klessig, a prof at Boyce Thompson Institute and Cornell University, used high-throughput screens to find proteins in the human body that bind to salicylic acid. GAPDH mainly plays a role in glucose metabolism, but it also helps regulate plants immune systems. Past research indicates several targets in plants are affected by salicylic acid and that many are translatable to humen, according to the release.
In the current study, scientists also observed that a natural derivative of salicylic acid from the Chinese medical herb licorice and a lab-synthesized derivative bind to GAPDH more effectively than salicylic acid.